CCM
OPRX icon

Channing Capital Management’s OptimizeRx OPRX Stock Holding History

Channing Capital Management’s Portfolio OPRX Stock Details OPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-22,899
Closed -$327K – 164
2023
Q2 		$327K Buy
+22,899
New +$326K 0.01% 137

Other funds holding OPRX

FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
GIPM
G2 Investment Partners Management New York $549M AUM 179.59% 1-Year Est. Return

Channing Capital Management's OPRX Position: Q3 2023 in Review

Channing Capital Management sold out of OptimizeRx (OPRX) in Q3 2023, closing a stake of 22,899 shares — an estimated $327K sold.

Channing Capital Management first reported a position in OPRX in Q2 2023 and held it in 1 quarter. The position peaked at $327K in Q2 2023. 94 funds tracked by Wall St. Rank hold OPRX as of Q3 2023.

  • Channing Capital Management reported no remaining OptimizeRx position as of Q3 2023 after selling out during the quarter.
  • Channing Capital Management sold 22,899 OptimizeRx shares in Q3 2023, an estimated $327K.
  • Channing Capital Management first reported a position in OptimizeRx in Q2 2023 and held it in 1 quarter.
  • Channing Capital Management's OptimizeRx position peaked at $327K in Q2 2023.
  • 94 funds tracked by Wall St. Rank held OptimizeRx as of Q3 2023.

Based on Channing Capital Management's 13F filing for Q3 2023, filed 13 Nov 2023.